Intellective Bio, Suzhou-Based CDMO and "Capacity Champion" with a RMB 5.9 Billion Valuation, Files for Hong Kong IPO

In June 2026, Intellective Bio officially filed its listing application with the Main Board of the Hong Kong Stock Exchange, with Dongxing Securities (Hong Kong) serving as the exclusive sponsor and CICC acting as the overall coordinator.

This biologic CDMO, founded in Suzhou in 2018, has carved out a development path distinct from the industry mainstream over eight years.

Amid a domestic landscape for large-molecule CDMOs characterized by the dominance of industry giants and intense, asset-light competition among SMEs, Intellective Bio has adhered to a strategy of proactive heavy-asset investment, establishing China's largest single-site stainless-steel biopharmaceutical production facility. Leveraging its robust manufacturing capacity and comprehensive end-to-end service capabilities, the company has firmly secured its position as a leader in the second tier of Chinese CDMOs.

Driven by its forward-looking strategic layout, Intellective Bio achieved the second-highest number of commercialized projects domestically and ranked third in antibody CDMO revenue in China in 2025, while its Changshu facility set a national industry record with a single-site capacity of 85,300 liters.

The fundamentals disclosed in the prospectus are highly representative of the industry: After six rounds of intensive financing, the post-money valuation has climbed to RMB 5.91 billion, with cumulative capital injections exceeding RMB 1 billion. The company is backed by top-tier institutions such as Legend Capital and Gaorong Capital, as well as multiple state-owned asset platforms across various regions. Meanwhile, the company has reported losses for three consecutive years, burdened by high levels of debt and financial costs, while the upfront investment pressure associated with its asset-heavy business model continues to manifest.

Leveraging over two decades of deep industrial expertise, founder Li Zhi has established a full-lifecycle service model centered on the philosophy of "One Molecule, Partnered Throughout." This approach, combined with a strategic pipeline layout featuring high-barrier modalities such as Antibody-Drug Conjugates (ADCs), constitutes the core strength driving the company's push into the capital markets. Consequently, the IPO journey of this emerging CDMO has become a key case study for observing the iterative evolution of China's domestic biological outsourcing industry.

When Intellective Bio entered the market in 2018, the landscape of China's biological CDMO industry had already taken shape, with overseas giants and leading domestic enterprises holding the majority of market share. New entrants to the industry generally adopted an asset-light, high-turnover model, focusing on low-barrier services such as small-scale and pilot clinical trials. By avoiding heavy asset investments and fulfilling short-term orders to rapidly generate revenue, this approach became the mainstream development strategy in the industry.

Li Zhi, with professional experience at leading pharmaceutical companies such as CSPC Pharmaceutical Group, Kanghong Pharmaceutical, and Innovent Biologics, has precisely identified structural shortcomings in the industry by leveraging his frontline experience in deeply participating in the industrialization and commercialization of multiple blockbuster biologics:

Most domestic CDMOs excel in early-stage drug process development and small- to pilot-scale technical services, but generally lack large-scale commercial manufacturing capabilities. This makes it difficult for them to meet the core demands of post-launch innovative drugs, such as scaled-up production, global regulatory compliance, and continuous process optimization. This industry landscape has led to persistent industrialization challenges for several major domestically developed blockbuster drugs after clinical approval, including insufficient production capacity, limited flexibility in production line switching, and slow regulatory ramp-up.

For small and medium-sized biotech companies, establishing independent manufacturing facilities involves pain points such as high capital investment and lengthy approval cycles. The persistent gap in commercial-scale production capacity has become a key bottleneck hindering the market launch of domestically produced innovative drugs.

Based on a rational assessment of industry trends, Intellective Bio established a differentiated strategy at its inception, eschewing the industry's mainstream asset-light startup model. Instead, it adopted a development logic centered on "production-driven, industrialization-first" principles, focusing on the high-barrier segment of compliant commercial-scale manufacturing.

The company initially planned three standardized production bases in Suzhou's Xiangcheng District, Suzhou Industrial Park, and Changshu, concentrating core capital on key production equipment such as large-scale stainless steel bioreactors to establish a GMP-compliant mass production system aligned with global regulatory standards and capable of supporting long-term, stable capacity ramp-up for drug manufacturing.

Addressing the industry pain point of the "disconnection between R&D and manufacturing," Intellective Bio has pioneered a full-lifecycle business model centered on the concept of "One Molecule, End-to-End Partnership." Its services span the entire value chain, from pre-IND process development and clinical trial manufacturing across all phases to BLA submission and commercial-scale production post-approval, thereby deeply aligning with customers' needs throughout the entire project lifecycle.

This business model has fostered exceptionally strong customer stickiness. Prospectus data shows that from 2023 to 2025, the company's collaborative projects increased from 122 to 197, covering 87 pre-IND projects, 84 Phase I/II clinical projects, and 24 core projects in Phase III and post-BLA stages. The repurchase rate among the top 30 clients reached 100%.

Furthermore, in contrast to the industry's passive business model of "accepting orders first, then arranging production," Intellective Bio adheres to the proactive layout of production capacity and qualification construction.

In 2019, the Xiangcheng production base was established and obtained a Drug Production License; in 2020, the base passed EU QP certification, securing qualifications for market access overseas; in 2021, the Suzhou Industrial Park base was completed and put into operation, the company was recognized as a High-Tech Enterprise, and its six proprietary technology platforms were gradually implemented and took shape.

The establishment of the Changshu super-large single-site facility has become the core capacity moat for Intellective Bio. Its single-unit production capacity of 85,300 liters for stainless steel reactors ranks first in China. Leveraging a unified GMP quality control system that can be flexibly adapted to meet the demands of large-scale mass production has become its core competitiveness in securing large commercial orders.

Leveraging robust commercial-scale manufacturing capabilities and a comprehensive compliance framework, Intellective Bio has become one of only two CDMOs in China with the commercial manufacturing capacity for more than three marketed drugs, establishing a scarce advantage in the high-value commercialized outsourcing sector.

According to Frost & Sullivan data, in 2025, Intellective Bio ranked second in the number of domestic commercialization projects and third in antibody CDMO revenue in China, firmly securing its position as the leading enterprise in the second tier of Chinese CDMOs.

Asset-heavy CDMOs operate in a capital-intensive sector, where continuous financial investment serves as the core support for capacity deployment and technological iteration. Since initiating its first round of financing in 2020, Intellective Bio has completed six intensive equity financing rounds within four years, establishing a diversified shareholder structure synergistically backed by market-oriented private equity (PE) firms and local state-owned capital. This tight alignment between capital pacing and the progress of capacity construction and technological upgrades has become a significant driver of the company's rapid rise.

Institutional entry pace aligns with Intellective Bio's capacity rollout milestones: In 2020, the Series A financing of RMB 112 million was secured, with Legend Capital and Boyuan Jiayu among the initial investors; the funds were primarily allocated to the Phase II construction of the Xiangcheng base, addressing the capital gap for early-stage capacity expansion. In 2021, the Series A+ and Series B financing rounds were completed, supporting the construction of the Suzhou Industrial Park base and the iteration of technology platforms, while core technologies such as ADC conjugation and cell culture gradually took shape. From 2022 to 2024, substantial Series C and C+ financing rounds were closed, with significant participation from local state-owned capital platforms in Quzhou and Changshu; all funds were dedicated to the construction of the Changshu super factory, enabling the company to establish a leading domestic single-site production capacity.

Multiple rounds of financing have driven the continuous rise in Intellective Bio's valuation, with its post-money valuation climbing from RMB 1.15 billion in Series A to RMB 5.91 billion in Series C+, achieving more than a fivefold increase over four years and raising a cumulative total of over RMB 1.231 billion.

Leveraging its full-cycle CDMO service model and six proprietary technology platforms—cell line development, media development, process scale-up, bioconjugation, complex antibody purification, and high-concentration formulation development—Intellective Bio has established comprehensive capabilities covering the four major classes of biologics: monoclonal antibodies, bispecific antibodies, fusion proteins, and antibody-drug conjugates (ADCs). On the technical front, the company achieves pre-optimization protein expression levels exceeding 10 g/L, with its proprietary media boosting protein expression by 40%. Its more than ten ADC conjugation processes support over thirty clinical projects, while 13 core invention patents have built a robust technological barrier.

Based on the above, by the end of 2025, Intellective Bio had cumulatively served over 200 pharmaceutical companies both domestically and internationally, implementing more than 400 collaborative projects.

As the collaborative pipeline matures, Intellective Bio's project structure has been continuously optimized, becoming the core driver of its performance improvement. In 2023, revenue from early-stage, low-margin pre-IND projects accounted for as high as 49.3% of Intellective Bio's total; by 2025, this proportion had declined significantly to 24.1%, while the share of revenue from high-value-added Phase III clinical, BLA, and commercialization projects rose to 52%, marking the completion of its business transformation from early-stage R&D contract services to late-stage, high-value manufacturing services.

In 2025, Intellective Bio's commercialized drug portfolio expanded from one to two products, directly driving a RMB 46.6 million reduction in gross loss and serving as the core driver of performance improvement. Currently, Intellective Bio has three partnered drugs approved for market entry, with commercial supply already realized; more than 20 projects have advanced to late-stage clinical development, and 197 ongoing R&D projects are progressing steadily, laying a solid foundation for sustained future performance realization.

However, an analysis of core financial data in recent years indicates that Intellective Bio has begun to show signs of reaching an inflection point for profitability, though it has not yet escaped its loss-making predicament. From 2023 to 2025, Intellective Bio's revenues were RMB 455 million, RMB 433 million, and RMB 484 million, respectively; gross losses amounted to RMB 33.828 million, RMB 65.270 million, and RMB 18.682 million, respectively; and net losses for the years were RMB 168 million, RMB 291 million, and RMB 215 million, respectively, resulting in a cumulative loss of RMB 674 million over the three-year period.

Furthermore, the inherent pressures of Intellective Bio's asset-heavy business model persist. Significant depreciation of fixed assets, ongoing compliance and operational maintenance costs, coupled with substantial financial expenses from preferred share redemption interest, have resulted in cumulative financial costs exceeding RMB 350 million over the past three years, continuously constraining profit margins. The risk associated with a concentrated customer base is also pronounced; in 2025, revenue from the top five customers accounted for 55.8% of total revenue, with the single largest customer contributing 33.6%.

The proceeds from this H-share IPO will be primarily used to upgrade and expand the Changshu base, further deepening the asset-heavy industrialization strategy. Intellective Bio will not construct new facilities in other locations, thereby maximizing the utilization of its existing GMP and EU QP compliance qualifications and effectively reducing the construction and certification costs associated with building new plants.

The fundraising strategy features a clear focus, primarily directed toward constructing two new drug substance production facilities, establishing a dedicated commercial-scale manufacturing workshop for antibody-drug conjugates (ADCs), and adding new biopharmaceutical process R&D laboratories and an AI-driven biomedical data center. The remaining funds will supplement daily operations. This approach precisely targets capacity expansion in high-barrier, high-margin sectors such as ADCs, addresses shortcomings in large-scale production capabilities for complex drugs, and further raises the ceiling for long-term growth.

The global ADC pipeline, representing next-generation star anti-tumor therapeutics, continues to expand rapidly, making it a core incremental track for the CDMO industry in the coming years. In China, high-end dedicated closed production lines for ADCs have long been in short supply.

Currently, Intellective Biologigs' conjugation technology platform has supported over 30 clinical projects. Upon completion of its dedicated commercial production line, the company will be able to rapidly fulfill various ADC commercial manufacturing orders, thereby creating a new growth curve. However, capacity expansion simultaneously introduces new operational pressures; the substantial additional investment in fixed assets will continue to incur depreciation costs, potentially further extending the timeline for the company to achieve overall profitability.

At this critical IPO juncture, multiple core uncertainties remain regarding Intellective Bio's future development. Over the next 1–2 years, the pace of late-stage pipeline conversion, the effectiveness of ADC capacity ramp-up, and the speed at which the profitability inflection point is realized will directly determine whether Intellective Bio can break free from its prolonged loss-making predicament and advance from being the leading player in the second tier of domestic CDMOs to becoming a core force in the industry.